Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.50 |
| ▸ | MTOR | P42345 | 7/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.50 |
| ▸ | PIK3R5 | Q8WYR1 | 3/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264884 | 0.90 | KLKB1 (0.41) | PIK3CAPIK3R1MTORPIK3CGPIK3R5 | |
| SCHEMBL1497386 | 0.86 | PIK3CA (0.42) | PIK3CAPIK3R1MTOR | |
| SCHEMBL2397822 | 0.85 | PIK3CA (0.49) | PIK3CAPIK3R1MTORPIK3CGPIK3R5 | |
| SCHEMBL1497344 | 0.84 | PIK3CA (0.54) | PIK3CAMTOR | |
| SCHEMBL12264891 | 0.78 | PIK3CA (0.56) | PIK3CAPIK3R1PIK3CD | |
| SCHEMBL12312702 | 0.77 | MTOR (0.55) | PIK3CAPIK3R1MTORPIK3CGPIK3R5 | |
| SCHEMBL12264887 | 0.75 | JAK3 (0.42) | PIK3CAPIK3R1MTOR | |
| SCHEMBL1497331 | 0.72 | JAK3 (0.41) | PIK3CAPIK3R1MTOR | |
| SCHEMBL2397384 | 0.71 | MTOR (0.51) | PIK3CAPIK3R1MTORPIK3CGPIK3R5 | |
| SCHEMBL1310732 | 0.70 | MTOR (0.76) | PIK3CAPIK3R1MTORPIK3CGPIK3R5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CA 1/4885PIK3R1 20/4885MTOR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.